Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Aleix Prat(Hospital Clínic de Barcelona)

Nature Communications

January 20, 2020

10.1038/s41467-019-14111-3

Cited by 118

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

|New England Journal of Medicine|2022|2.5k

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

|Breast Cancer Research|2010|2.1k

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

|Annals of Oncology|2018|1.2k

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

|Annals of Oncology|2021|799

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

|Cancer Discovery|2012|622